Monoclonal antibodies work through several mechanisms. They can directly target cancer cells and mark them for destruction by the immune system. Some monoclonal antibodies can block growth signals to cancer cells or deliver toxic substances directly to the cancer cells. For example, Bevacizumab blocks the vascular endothelial growth factor (VEGF), preventing the growth of blood vessels that supply the tumor.
